Indivior PLC
INDV
查看详细走势图
36.160USD
-0.190-0.52%
收盘 12/24, 16:00（美东）报价延迟15分钟
4.52B总市值
36.76市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.52%
5天
+1.74%
1月
+9.24%
6月
+163.36%
今年开始到现在
+190.91%
1年
+201.58%
查看详细走势图
TradingKey Indivior PLC股票评分
单位: USD 更新时间: 2025-12-24操作建议
Indivior PLC当前公司基本面数据相对健康，增长潜力很大。当前估值合理，在药品行业排名22/158位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价37.86。中期看，股价处于上升通道。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Indivior PLC评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
7
位分析师
买入
评级
37.857
目标均价
+3.43%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Indivior PLC亮点
亮点风险
Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.
业绩高增长
公司营业收入稳步增长，连续3年增长31.85%
业绩转盈
公司业绩转盈，最新年度盈利美元
估值高估
公司最新PE估值36.76，处于3年历史高位
机构加仓
最新机构持股118.02M股，环比增加2.08%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值3.44M
Indivior PLC新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Indivior PLC简介
Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.
公司代码INDV
公司Indivior PLC
CEOCiaffoni (Joseph J)
网址https://www.indivior.com/en
常见问题
Indivior PLC(INDV)的当前股价是多少？
Indivior PLC(INDV)的当前股价是 36.160。
Indivior PLC的股票代码是什么？
Indivior PLC的股票代码是INDV。
Indivior PLC股票的52周最高点是多少？
Indivior PLC股票的52周最高点是38.000。
Indivior PLC股票的52周最低点是多少？
Indivior PLC股票的52周最低点是7.620。
Indivior PLC的市值是多少？
Indivior PLC的市值是4.52B。
Indivior PLC的净利润是多少？
Indivior PLC的净利润为2.00M。
现在Indivior PLC(INDV)的股票是买入、持有还是卖出？
根据分析师评级，Indivior PLC(INDV)的总体评级为买入，目标价格为37.857。
Indivior PLC(INDV)股票的每股收益（EPS TTM）是多少
Indivior PLC(INDV)股票的每股收益（EPS TTM）是0.984。
相关品种
